Maternal Whooping Cough Vaccine Transfers Crucial Antibodies to Newborns, Study Finds
Table of Contents
A groundbreaking new study reveals that vaccinating pregnant women against whooping cough not only transfers protective antibodies to their babies, but these antibodies are also present in the nasal passages – the primary entry point for the infection. This finding, published in Clinical Gastroenterology and Hepatology, underscores the effectiveness of this vaccination strategy in safeguarding infants during their most vulnerable period.
Since 2019, the Netherlands has offered a whooping cough vaccine, known as the 22-week vaccine, to expectant mothers to protect their future children. The research, conducted by Radboud University Medical Center (Netherlands) and the Gambia Medical Research Council Unit (Gambia), provides compelling evidence supporting this public health initiative.
Protecting the Most Vulnerable
“We administer this vaccine to protect babies from whooping cough promptly after birth,” explains an immunologist at Radboud University Medical Center. “In the first weeks of life, babies are extremely vulnerable and too small to be vaccinated. That is why we vaccinate the mother during pregnancy.”
The study involved 343 mothers and their babies, with half of the pregnant women receiving the whooping cough vaccine. Researchers discovered that antibodies transmitted through the placenta where successfully detected in the babies’ nasal mucosa. This is a significant breakthrough, as it had not been previously demonstrated that these antibodies reach this critical location.
A Global Health Challenge
While whooping cough, also known as pertussis, is largely controlled in Europe, it remains a significant threat to infants worldwide. The World Health Association estimates that between 200,000 and 300,000 people die from the disease annually, with the vast majority of fatalities occurring in low- and middle-income countries where access to quality vaccines is limited.
“Mothers vaccinated during pregnancy transmitted antibodies through the placenta, which were subsequently detected in the baby’s nasal mucosa,” a researcher confirmed. This passive immunity provides a crucial bridge of protection until infants are old enough to receive their own vaccinations.
Whole-Cell vs. Acellular Vaccines: A Matter of Immunity Duration
The study also shed light on the comparative effectiveness of different types of whooping cough vaccines. Researchers found that babies who received a whole-cell vaccine at 8,12,and 16 weeks developed,on average,a stronger immune response than those who received an acellular vaccine,which has been standard in Europe as 2005.
“The difference is that a whole-cell vaccine contains the complete, but inactivated, pertussis bacteria, while an acellular vaccine contains only a few purified components of the bacteria,” explains an immunologist. “Our findings suggest that whole-cell vaccines could contribute to longer-lasting immune protection.”
A postdoctoral researcher at Radboud University Medical Center added, “Acellular vaccines tend to cause fewer side effects, but often also offer shorter protection. Our findings suggest that whole-cell vaccines could contribute to longer-lasting immune protection.”
Implications for Public Health policy
For the Netherlands, this research reinforces the importance of the 22-week vaccine program, providing immediate protection to newborns. In low-income countries,the findings suggest that implementing pertussis vaccination during pregnancy could dramatically reduce infant mortality. Furthermore, the results support the World Health Organization’s recommendation to continue using whole-cell vaccines in countries where they are still employed, given their potential for longer-lasting immunity.
This study represents a significant step forward in our understanding of maternal vaccination and its impact on infant health, offering a powerful tool in the global fight against whooping cough.
Worth a look
